The study explores the impact of a digital app for the self-management of (peri-)menopausal disorders. A total of 224 participants were randomized into an intervention and a control group. Findings indicate that the app offers beneficial effects on menopausal symptoms and menopause-specific quality-of-life. The study also provided valuable insights for the design of future larger trials and highlights the promising potential of the app to enhance individualized care.

Inclusion Criteria:

• Legal capacity
• Residency in Germany
• Female sex
• Age ≥18 years
• Known and medically confirmed (peri-)menopausal disorder (N95.1, N95.3, N95.8, N95.9)
• Ownership of a smartphone and ability to use it
• Internet access for app usage and questionnaire completion
• Email address for registration
• Willingness to complete questionnaires online
• Motivation for regular app usage
• Sufficient proficiency in the German language
• Absence of exclusion criteria

Exclusion Criteria:

• Changes in hormone therapy within eight weeks before the start of the study and/or planned within the next 12 weeks
• Changes in antidepressant treatment within eight weeks before the start of the study and/or planned within the next 12 weeks
• Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
• Current participation in other clinical studies
• Failure to meet the inclusion criteria